Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Net Common Stock Issuance

Last Annual Value

8.26M

3-Year CAGR

9%

5-Year CAGR

%

10-Year CAGR

%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Net Common Stock Issuance

NTRB · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
8.26M
N/A5.5%47.0% 
264.00K
-81.6%-68.8%N/A
93.64M
N/A-12.8%N/A
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
0.00
N/AN/AN/A
1.00K
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
75.50M
480.5%-20.5%N/A
28.54M
30.9%-7.7%N/A
12.23M
157.5%-22.6%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
4.44M
-33.4%-48.5%N/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
65.84M
21.3%-12.9%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
65.58M
325.2%8.9%18.2%
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15